| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 52 | 2023 | 152 | 14.090 |
Why?
|
| Anti-Asthmatic Agents | 17 | 2023 | 31 | 4.800 |
Why?
|
| Hypersensitivity | 7 | 2023 | 38 | 2.550 |
Why?
|
| Physicians | 6 | 2022 | 105 | 2.520 |
Why?
|
| Adrenal Cortex Hormones | 13 | 2023 | 95 | 2.490 |
Why?
|
| Telemedicine | 7 | 2023 | 84 | 2.430 |
Why?
|
| Medication Adherence | 12 | 2023 | 49 | 2.240 |
Why?
|
| Patient Education as Topic | 9 | 2021 | 120 | 2.210 |
Why?
|
| Burnout, Professional | 4 | 2022 | 26 | 2.160 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 75 | 1.900 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 78 | 1.890 |
Why?
|
| Humans | 79 | 2023 | 22838 | 1.620 |
Why?
|
| Child | 29 | 2023 | 1154 | 1.560 |
Why?
|
| Community Health Workers | 7 | 2022 | 34 | 1.310 |
Why?
|
| Administration, Inhalation | 14 | 2022 | 37 | 1.240 |
Why?
|
| Adolescent | 24 | 2023 | 1875 | 1.180 |
Why?
|
| Pandemics | 11 | 2022 | 202 | 1.060 |
Why?
|
| Behavior Therapy | 2 | 2017 | 85 | 0.940 |
Why?
|
| Caregivers | 7 | 2019 | 182 | 0.910 |
Why?
|
| Nebulizers and Vaporizers | 8 | 2022 | 21 | 0.850 |
Why?
|
| Mobile Applications | 2 | 2020 | 27 | 0.770 |
Why?
|
| Betacoronavirus | 5 | 2020 | 65 | 0.760 |
Why?
|
| Emergency Service, Hospital | 8 | 2020 | 253 | 0.740 |
Why?
|
| Biological Products | 1 | 2022 | 31 | 0.720 |
Why?
|
| Adult | 20 | 2023 | 6892 | 0.660 |
Why?
|
| Environmental Exposure | 2 | 2018 | 18 | 0.650 |
Why?
|
| Allergy and Immunology | 4 | 2020 | 5 | 0.650 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 16 | 0.650 |
Why?
|
| Poverty | 3 | 2020 | 83 | 0.640 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 1013 | 0.640 |
Why?
|
| Female | 31 | 2023 | 12901 | 0.620 |
Why?
|
| Male | 30 | 2023 | 12415 | 0.600 |
Why?
|
| Parents | 2 | 2018 | 106 | 0.580 |
Why?
|
| Emigrants and Immigrants | 2 | 2018 | 19 | 0.570 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 34 | 0.570 |
Why?
|
| Health Literacy | 4 | 2021 | 83 | 0.560 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 6 | 0.560 |
Why?
|
| Registries | 1 | 2019 | 173 | 0.550 |
Why?
|
| Self Care | 5 | 2020 | 85 | 0.540 |
Why?
|
| Decision Making | 1 | 2018 | 176 | 0.510 |
Why?
|
| Child, Preschool | 8 | 2022 | 566 | 0.490 |
Why?
|
| Assertiveness | 1 | 2015 | 7 | 0.480 |
Why?
|
| Urban Population | 5 | 2013 | 125 | 0.450 |
Why?
|
| United States | 9 | 2023 | 1758 | 0.440 |
Why?
|
| Chicago | 7 | 2019 | 812 | 0.440 |
Why?
|
| Social Support | 2 | 2021 | 174 | 0.410 |
Why?
|
| Family | 3 | 2021 | 85 | 0.400 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 11 | 0.400 |
Why?
|
| Patient Compliance | 2 | 2011 | 146 | 0.390 |
Why?
|
| Minority Groups | 4 | 2019 | 66 | 0.390 |
Why?
|
| Immunization, Passive | 5 | 2023 | 10 | 0.380 |
Why?
|
| MP3-Player | 2 | 2013 | 5 | 0.380 |
Why?
|
| House Calls | 3 | 2021 | 15 | 0.360 |
Why?
|
| Electronics | 2 | 2021 | 9 | 0.350 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 96 | 0.340 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 35 | 0.340 |
Why?
|
| Computer Security | 2 | 2020 | 5 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 145 | 0.330 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 13 | 0.330 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 255 | 0.320 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 219 | 0.320 |
Why?
|
| Hospitalization | 3 | 2022 | 286 | 0.310 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2009 | 1 | 0.300 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 14 | 0.300 |
Why?
|
| Athletes | 1 | 2009 | 52 | 0.280 |
Why?
|
| Communication Barriers | 1 | 2007 | 3 | 0.270 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 165 | 0.270 |
Why?
|
| Quality Improvement | 3 | 2018 | 127 | 0.270 |
Why?
|
| Language | 1 | 2007 | 57 | 0.260 |
Why?
|
| Research Design | 2 | 2019 | 156 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 800 | 0.230 |
Why?
|
| Electronic Health Records | 3 | 2020 | 64 | 0.230 |
Why?
|
| Middle Aged | 8 | 2022 | 7869 | 0.220 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 62 | 0.210 |
Why?
|
| Albuterol | 4 | 2022 | 14 | 0.210 |
Why?
|
| Urticaria | 1 | 2023 | 4 | 0.200 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 6 | 0.200 |
Why?
|
| One Health | 1 | 2023 | 1 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 25 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 32 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2020 | 57 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2022 | 2929 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2023 | 63 | 0.190 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 121 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 3 | 0.190 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 12 | 0.180 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 40 | 0.180 |
Why?
|
| Vaccination | 1 | 2022 | 26 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 48 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 758 | 0.180 |
Why?
|
| Anaphylaxis | 1 | 2021 | 11 | 0.170 |
Why?
|
| Biomedical Technology | 1 | 2021 | 3 | 0.170 |
Why?
|
| Depression | 3 | 2020 | 365 | 0.170 |
Why?
|
| Endpoint Determination | 1 | 2021 | 22 | 0.170 |
Why?
|
| Mental Health | 2 | 2020 | 94 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 96 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 32 | 0.170 |
Why?
|
| Self Report | 1 | 2021 | 193 | 0.170 |
Why?
|
| Self-Management | 2 | 2017 | 9 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 5 | 0.160 |
Why?
|
| Clinical Coding | 1 | 2020 | 4 | 0.160 |
Why?
|
| Remote Sensing Technology | 1 | 2020 | 3 | 0.160 |
Why?
|
| Confidentiality | 1 | 2020 | 4 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 189 | 0.160 |
Why?
|
| Tiotropium Bromide | 1 | 2020 | 2 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 3 | 0.160 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 4 | 0.160 |
Why?
|
| Lung | 1 | 2021 | 137 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 18 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 34 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2019 | 171 | 0.160 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 1 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 117 | 0.160 |
Why?
|
| Family Relations | 1 | 2019 | 12 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2023 | 373 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 168 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 11 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 20 | 0.150 |
Why?
|
| Pediatrics | 1 | 2019 | 37 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 71 | 0.140 |
Why?
|
| Outpatients | 3 | 2023 | 56 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 243 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 375 | 0.140 |
Why?
|
| Patient Participation | 1 | 2018 | 43 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2018 | 17 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 1966 | 0.140 |
Why?
|
| Volunteers | 1 | 2017 | 3 | 0.130 |
Why?
|
| Community Participation | 1 | 2017 | 13 | 0.130 |
Why?
|
| Education, Distance | 1 | 2017 | 14 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2017 | 24 | 0.130 |
Why?
|
| Cell Phone | 1 | 2017 | 6 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2016 | 24 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 310 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2966 | 0.120 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 15 | 0.120 |
Why?
|
| Health Status | 3 | 2021 | 200 | 0.110 |
Why?
|
| Smartphone | 1 | 2015 | 14 | 0.110 |
Why?
|
| Young Adult | 4 | 2022 | 1645 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 544 | 0.100 |
Why?
|
| Aged | 3 | 2022 | 7415 | 0.100 |
Why?
|
| Animals | 2 | 2023 | 3311 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 554 | 0.100 |
Why?
|
| Peer Group | 1 | 2013 | 32 | 0.100 |
Why?
|
| Housing | 1 | 2013 | 15 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 162 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 289 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 373 | 0.090 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2012 | 7 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2017 | 365 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 636 | 0.090 |
Why?
|
| School Health Services | 1 | 2011 | 17 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 54 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 124 | 0.090 |
Why?
|
| Students | 1 | 2011 | 37 | 0.090 |
Why?
|
| Consensus | 2 | 2021 | 81 | 0.080 |
Why?
|
| Ambulatory Care | 2 | 2022 | 66 | 0.080 |
Why?
|
| Mexican Americans | 1 | 2011 | 26 | 0.080 |
Why?
|
| Anti-Allergic Agents | 1 | 2010 | 2 | 0.080 |
Why?
|
| Androstadienes | 1 | 2010 | 8 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 8 | 0.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 6 | 0.080 |
Why?
|
| Acetates | 1 | 2010 | 16 | 0.080 |
Why?
|
| Anxiety | 2 | 2021 | 142 | 0.080 |
Why?
|
| Puerto Rico | 3 | 2014 | 12 | 0.080 |
Why?
|
| Disease Progression | 2 | 2022 | 528 | 0.080 |
Why?
|
| Allergens | 2 | 2023 | 16 | 0.070 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 25 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 349 | 0.070 |
Why?
|
| Music | 1 | 2008 | 19 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2021 | 31 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 13 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 9 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 1490 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 13 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 43 | 0.050 |
Why?
|
| Irritants | 1 | 2023 | 1 | 0.050 |
Why?
|
| Community-Based Participatory Research | 2 | 2014 | 32 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 68 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 67 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 3 | 0.050 |
Why?
|
| Dry Powder Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Metered Dose Inhalers | 1 | 2022 | 4 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 29 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 202 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 231 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 43 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 102 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 8 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 24 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 87 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 90 | 0.040 |
Why?
|
| London | 1 | 2020 | 2 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 40 | 0.040 |
Why?
|
| Terbutaline | 1 | 2020 | 1 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 16 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Professionalism | 1 | 2020 | 3 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 30 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 6 | 0.040 |
Why?
|
| Guilt | 1 | 2020 | 5 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 20 | 0.040 |
Why?
|
| Suicide | 1 | 2020 | 12 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 15 | 0.040 |
Why?
|
| Grief | 1 | 2020 | 18 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 107 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 26 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 50 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 315 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 273 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 45 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 71 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 78 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 97 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 121 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 44 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 96 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 124 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 58 | 0.040 |
Why?
|
| Health Promotion | 1 | 2020 | 123 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 209 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 219 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 160 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 1407 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 424 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 78 | 0.030 |
Why?
|
| Persuasive Communication | 1 | 2017 | 1 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 21 | 0.030 |
Why?
|
| Sinusitis | 1 | 2019 | 151 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 29 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 53 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 71 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 109 | 0.030 |
Why?
|
| Schools | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2013 | 6 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 1993 | 1 | 0.020 |
Why?
|
| Saliva | 1 | 2013 | 47 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 40 | 0.020 |
Why?
|
| Work of Breathing | 1 | 2012 | 5 | 0.020 |
Why?
|
| Vital Signs | 1 | 2012 | 3 | 0.020 |
Why?
|
| Spirometry | 1 | 2012 | 9 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 163 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 210 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 206 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 100 | 0.020 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sulfides | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2010 | 26 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 220 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 377 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 441 | 0.010 |
Why?
|
| Vietnam | 1 | 1993 | 7 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 153 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 228 | 0.010 |
Why?
|
| Alcoholism | 1 | 1993 | 64 | 0.010 |
Why?
|
| Veterans | 1 | 1993 | 87 | 0.010 |
Why?
|